Cardiac Magnetic Resonance Feature-Tracking Identifies Preclinical Abnormalities in Hypertrophic Cardiomyopathy

Francesco Negri1, Giuseppe Damiano Sanna2, Giulia Di Giovanna3

  • 1Cardiology Department, University Hospital "Santa Maria della Misericordia," Azienda Sanitaria Universitaria Integrata Friuli Centrale, Udine, Italy (F.N., M.I.).

Insights

Cardiac magnetic resonance feature tracking (FT) can identify reduced myocardial strain in individuals with subclinical hypertrophic cardiomyopathy (HCM). This technique shows promise for early disease detection before overt left ventricular hypertrophy develops.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Genetics

Background:

  • Cardiac magnetic resonance feature tracking (FT) is established for assessing overt hypertrophic cardiomyopathy (HCM).
  • Its utility in carriers of sarcomere gene mutations without evident left ventricular hypertrophy (subclinical HCM) remains largely unexplored.

Purpose of the Study:

  • To investigate the role of FT in detecting subclinical HCM.
  • To evaluate FT's ability to differentiate subclinical HCM patients from healthy controls.

Main Methods:

  • A multicenter case-control study involving 38 subclinical HCM subjects and 42 healthy volunteers.
  • Comprehensive cardiac magnetic resonance imaging (CMR) with two-dimensional FT analysis of left ventricular (LV) global radial, circumferential, and longitudinal strain.
  • Receiver operating characteristic (ROC) curve analysis to assess diagnostic performance.

Main Results:

  • Subclinical HCM patients exhibited significantly reduced global radial, circumferential, and longitudinal strain compared to controls (P<0.0001 for all).
  • These differences remained significant even in subjects without other ECG or CMR abnormalities.
  • ROC analysis demonstrated good to excellent diagnostic performance for FT parameters in discriminating subclinical HCM (AUCs ranging from 0.838 to 0.966).

Conclusions:

  • Cardiac magnetic resonance FT-derived strain parameters are consistently diminished in subclinical HCM patients.
  • FT analysis holds potential as a valuable tool for identifying HCM during its preclinical phase.
Abstract

Related Concept Videos

Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...